Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in PatieInformation on Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patie under Irritable Bowel Syndrome section of the Health Articles & Reviews; CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of ... |
 |
|
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patie
by Anthony F Boyle 09-13-2010, 10:47 PM
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation (IBS-C). Analyses of the data indicate ...
More... |
Views 16
Comments 0
|
|
| Bookmarks |
| Currently Active Users Viewing This Article: 1 (0 members and 1 guests) | |
| Article Tools | |
| Display Modes | |
|
|
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
Linear Mode
